OPTIMAL TREATMENT OF RETINAL DISEASE LEVERAGING NOVEL DELIVERY TECHNOLOGY
Everads: more effective, durable treatment for retinal diseases.
Our technology facilitates targeted, rapid delivery of therapy via the emerging suprachoroidal delivery route. Leveraging our technology, we are developing treatments to improve efficacy and reduce treatment burden, and also partnering with leading pharmaceutical and biotech companies to enable delivery of novel therapies using our technology.
About Everads
Everads is an emerging startup with novel delivery technology to treat retinal diseases via suprachoroidal administration and is developing an early-stage pipeline that leverages our technology. Our technology enables delivery of therapy to the choroid and retina via the suprachoroidal space (SCS)….
Everads News
December 2024
Overview of Clinical Data using Everads Technology Featured at Floretina2024
Clinical experience using Everads’ suprachoroidal delivery injector was presented at the Floretina2024 meeting held December 5-8. In a symposium moderated by Dr. Quan Nguyen and titled Further Progress on Suprachoroidal Delivery for Ocular Diseases, Dr. Yoreh Barak, Head of Retina at Rambam Medical Center and PI in Everads’ clinical trial, presented an overview of Everads’ technology and results from the ongoing clinical trial.
November 2024
Everads Suprachoroidal Delivery Featured at OIS XIV Conference
​
Everads’ suprachoroidal delivery platform was presented at the Ophthalmology Innovation Source (OIS) 14th annual conference held in San Diego on November 22-23rd (ois.net/ois-xiv/). As part of a panel session titled “Spotlight on Suprachoroidal Drug Delivery”, Moshe Weinstein, Everads CEO, shared recent updates from the company’s ongoing clinical trial, as well as provided an overview of Everads’ internal and license-partner pipeline.
January 2025
Everads Leads Suprachoroidal Delivery Workshop and Delivers Corporate Presentation at the 3rd Ophthalmic Drug Delivery Summit in San Francisco
Everads Therapy’s CEO, Moshe Weinstein, led a workshop on suprachoroidal delivery, and provided a corporate update, at the 3rd Ophthalmic Drug Delivery Summit held in San Francisco Jan 28-30, 2025. Moshe also participated in a panel discussion with representatives from other players in the suprachoroidal delivery space, including Clearside, Oxular and Genentech. Including the deep dive into suprachoroidal delivery, Moshe also provided an update from Everads’ ongoing clinical trial, as well as data from the company’s internal JAK inhibitor program.
